Pfizer, Teva running short on antibiotic azithromycin amid COVID-19 therapy hunt

23rd April 2020 Uncategorised 0

In the hunt for a COVID-19 therapy, some researchers have hit upon a combination of antimalarial hydroxychloroquine and antibiotic azithromycin as a potential answer. So far, clinical results have been mixed at best—but demand for azithromycin has still been sky-high, and drugmakers are feeling the pinch.

More: Pfizer, Teva running short on antibiotic azithromycin amid COVID-19 therapy hunt
Source: fierce